Gapping down
In reaction to disappointing earnings/guidance: TCS -27.6%, CUDA -26.4%, AEO -11.1%, GHDX -8.9%, QDEL -8.1%, GPS -7.4%, QRVO -5.2%
Select metals/mining stocks trading lower: HMY -8.3%, KGC -5%, AUY -4.3%, ABX -3.3%, SAND -3.3%, GG -2.5%, GDX -2.4%, GFI -2.2%, NEM -1.9%, SLV -1.5%, GOLD -0.8%
Other news: SFXE -32% (disclosed it assigned all of its rights as lender under SFXE's $30 mln revolving credit facility to Catalyst Fund Limited Partnership), SORL -8.7% (announces that the consortium has withdrawn its previously submitted non-binding 'going-private' offer due to market conditions), COLL -2.7% (prices a 2.75 mln share public offering of common stock at $20.00/share), NVCR-1.3% (submitted a premarket approval partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency for the use of Optune in patients with newly diagnosed glioblastoma), SWKS -0.9% (following CRUS guidance), AVGO -0.5% (following CRUS guidance), .
Analyst comments: N/
A
In reaction to disappointing earnings/guidance: TCS -27.6%, CUDA -26.4%, AEO -11.1%, GHDX -8.9%, QDEL -8.1%, GPS -7.4%, QRVO -5.2%
Select metals/mining stocks trading lower: HMY -8.3%, KGC -5%, AUY -4.3%, ABX -3.3%, SAND -3.3%, GG -2.5%, GDX -2.4%, GFI -2.2%, NEM -1.9%, SLV -1.5%, GOLD -0.8%
Other news: SFXE -32% (disclosed it assigned all of its rights as lender under SFXE's $30 mln revolving credit facility to Catalyst Fund Limited Partnership), SORL -8.7% (announces that the consortium has withdrawn its previously submitted non-binding 'going-private' offer due to market conditions), COLL -2.7% (prices a 2.75 mln share public offering of common stock at $20.00/share), NVCR-1.3% (submitted a premarket approval partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency for the use of Optune in patients with newly diagnosed glioblastoma), SWKS -0.9% (following CRUS guidance), AVGO -0.5% (following CRUS guidance), .
Analyst comments: N/
A